RXRX Q4 2022 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RXRXRecursion Pharmaceuticals, Inc.

$2B

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+447.0% YoY

Gross Profit

$3M20.7% margin

Operating Income

-$61M-445.9% margin

Net Income

-$57M-420.4% margin

EPS (Diluted)

$-0.31

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$53M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$701M

Total Liabilities

$215M

Stockholders' Equity

$486M

Cash & Equivalents

$550M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$3M	+447.0%
Gross Profit	$3M	$3M	+13.4%
Operating Income	-$61M	-$65M	+6.1%
Net Income	-$57M	-$65M	+11.5%

Revenue Segments

License and Service

$14M100%